Drug policy for visceral leishmaniasis: a cost-effectiveness analysis

V Vanlerberghe, G Diap, PJ Guerin, F Meheus, S Gerstl, P Van der Stuyft, M Boelaert

    Research output: Contribution to journalA1: Web of Science-articlepeer-review

    Original languageEnglish
    JournalTropical Medicine and International Health
    Volume12
    Issue number2
    Pages (from-to)274-283
    ISSN1360-2276
    DOIs
    Publication statusPublished - 2007

    Keywords

    • B780-tropical-medicine
    • Protozoal diseases
    • Leishmaniasis
    • Visceral
    • Kala azar
    • Drug therapy
    • Antiprotozoal agents
    • Cost-effectiveness
    • Amphotericin B
    • Miltefosine
    • Ambisome
    • Antimonials
    • Sodium stibogluconate
    • Generics
    • Adverse effects
    • Drug resistance

    Cite this